8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


                                 October 7, 2004

                Date of Report (Date of earliest event reported)


                                 ORAGENICS, INC.

             (Exact name of registrant as specified in its charter)


          Florida                     000-50614                59-3410522

(State or other jurisdiction         (Commission              (IRS Employer
     of incorporation)               File Number)           Identification No.)


                              12085 Research Drive
                             Alachua, Florida 32615

           (Address of principal executive offices including zip code)


                                 (386) 418-4018

               Registrant's telephone number, including area code


- --------------------------------------------------------------------------------
                                      None
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)
- --------------------------------------------------------------------------------

================================================================================


ITEM 7.01 REGULATION FD DISCLOSURE

      Oragenics, Inc. announces that it will de-list its common stock from the
TSX Venture Exchange and solely list its shares on the American Stock Exchange.


ITEM 9.01 FINANCIAL INFORMATION AND EXHIBITS

             -----------------------------------------
             Exhibit No.     Description
             -----------------------------------------
             99.1            Press Release
             -----------------------------------------


                                   SIGNATURES

      In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized on this 7th day of October, 2004.

                                       ORAGENICS, INC.
                                       (Registrant)

                                       BY: /s/ Mento A. Soponis

                                           Mento A. Soponis
                                           President and Chief Executive Officer

EX-99.1

Contact:

Chuck Soponis                                                      Joan Kureczka
Chief Executive Officer                               Kureczka/Martin Associates
Oragenics, Inc.                                                   (415) 821-2413
(386) 418-4018                                             Jkureczka@comcast.net

FOR IMMEDIATE RELEASE

              ORAGENICS, INC. TO DE-LIST FROM TSX VENTURE EXCHANGE

ALACHUA, FL (October 7, 2004) - Oragenics, Inc. (AMEX:ONI; TSX-V:ORA.U) today
announced that effective on October 13, 2004, the Company will de-list from the
TSX Venture Exchange and trade exclusively on the American Stock Exchange
("AMEX") under the symbol "ONI..

Oragenics, Inc. has been listed on the TSX Venture Exchange (symbol "ORA.U")
since June 24, 2003, when the Company completed an initial public offering of
its common stock. On May 20, 2004, Oragenics, Inc. stock began trading on the
American Stock Exchange (symbol "ONI"). Since that time, the volume of
Oragenics' shares being traded on the TSX Venture Exchange has steadily
declined. Oragenics shares will continue to be traded on the American Stock
Exchange under the symbol "ONI."

"We appreciate the opportunity of having our stock traded on the TSX Venture
Exchange," said Chuck Soponis, Oragenics chief executive officer. "The TSX
market provided excellent support for our shares and the staff at the venture
exchange has been consistently helpful and cooperative. However, we believe that
a sole listing on the AMEX will diminish investor confusion, reduce our filing
costs, and provide a satisfactory alternative for our Canadian investors."


About Oragenics

Oragenics, Inc. is an emerging biotechnology company focused on the development
and licensure of innovative products and technologies for improving human
health. The company's lead product is a novel oral rinse for the prevention of
tooth decay, which is anticipated to enter clinical trials in 2004. The company
is also developing a novel antibiotic with broad-spectrum activity against
gram-positive bacteria and a probiotic product aimed at maintaining oral health.
The company is headquartered in Alachua, Florida. For more information about
Oragenics, please consult the company's website at www.oragenics.com.


Safe Harbor Statement Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements which reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe", "expect", "anticipate",
"intend", "estimate", "project" and similar expressions which do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to (1)
the ability to successfully complete development and commercialization of
Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic,
and probiotic product for oral health; (2) the ability to obtain substantial
additional funding; (3) the ability to develop and commercialize products before
competitors;(4) the ability to develop commercial products with the in-licensed
technology; and (5) other factors detailed from time to time in filings with the
Securities and Exchange Commission. We expressly disclaim any responsibility to
update forward-looking statements. The TSX Venture Exchange has not reviewed and
does not accept responsibility for the adequacy or accuracy of this news
release.
                                      # # #